March 2016 Monthly Test Updates

Published on 03/01/16

New Test Launches and Updates

The following new tests are now available:
  • TP Maintain An Established Prenatal Culture (CV or AF)
  • TB Maintain An Established Culture (Not Prenatal)

The below test updates are live:

  • UA Amino Acid Profile, Quantitative, Urine – changed turnaround time to 7 days
  • MM350 Hereditary Neuropathies: Sequencing Panel – CPT code updated
  • MD350 Hereditary Neuropathies: Deletion/Duplication Panel – CPT code updated
  • MD Myotonic Dystrophy: CTG Repeat Analysis – reference range updated
  • TA Cell Culture Only - Amniotic Fluid or CVS – Name changed
  • UB Fabry Disease: Alpha-Galactosidase Enzyme Activity, Dried Blood Spot – discontinued
  • BC Maple Syrup Urine Disease: BCKD Enzyme Activity, Lymphoblasts – discontinued
  • ZU Maple Syrup Urine Disease: BCKD Enzyme Activity, Fibroblasts – discontinued
  • CM080 Targeted Tumor Mutation: Sequencing Panel – discontinued
  • CM081 Targeted Colorectal Tumor Mutation: Sequencing Panel – discontinued
  • CM082 Targeted Lung Tumor Mutation: Sequencing Panel –discontinued
  • CM083 Targeted Melanoma Mutation: Sequencing Panel –discontinued
  • CM084 Targeted Gastric Tumor Mutation: Sequencing Panel –discontinued
  • CM085 Targeted Ovarian Tumor Mutation: Sequencing Panel – discontinued

Test Requisitions - Things to Remember
Not completing a test requisition form entirely can sometimes lead to unnecessary delays in testing. Below are the most commonly missed items:

  • ICD10 codes
  • Policy holder name and date of birth
  • If any authorizations are obtained for the patient, please include a copy of the authorizations with the requisition.
  • Medicare patients must have a signed Advance Beneficiary Notice of Non-coverage (ABN) included with the requisition, except for following BRCA-related test codes: MM070, MM071, MM072, and MM208. Please note, EGL does not pre-verify benefits for patients with Medicare.
  • Signature in the “Authorization to Assign Benefits” section
  • Front and back copy of the patient’s insurance card
  • Billing pages - regardless of the person or entity to be billed, please complete this information.


Prior Authorization Reminder
When it is determined that a prior authorization is needed for testing, the sample will be placed on a billing hold. EGL will notify the client as to what is required and help with any necessary paperwork.

New and Updated Gene Panels

Industry-leading number of gene panels

EGL Next Generation Sequencing Panels include comprehensive, evidence-based gene lists, improved turnaround times, and reduced pricing.